HeartBeam AIMIGo

HeartBeam, Inc. is a medical technology company based in Santa Clara, California, listed on NASDAQ (BEAT). It focuses on detecting and monitoring critical cardiac conditions outside the hospital, with a cable-free 3D ECG platform protected by more than 20 issued patents.

The AIMIGo is a credit card-sized device that records ECG signals in three non-coplanar directions and synthesizes them into a 12-lead ECG. A patient app guides the recording, the data goes to the cloud, and an on-call physician reviews it through a clinician portal. The 12-lead software received FDA 510(k) clearance in December 2025 for assessing certain arrhythmias, and a limited market release targets concierge and preventive cardiology groups.

• Synthesized 12-lead ECG: converts three-direction signals into a 12-lead ECG for manual arrhythmia assessment.
• Cable-free device: credit card-sized unit that is portable and needs no lead wires.
• Patient app: gives step-by-step guidance for taking a recording.
• Cloud transfer: recordings are uploaded for remote review.
• Physician review: an on-call physician reviews recordings through a clinician portal.
• Extended-wear patch: a working prototype of a 12-lead ECG patch has been completed.

Private cardiology clinics offering post-visit rhythm checks for patients with palpitations. Health check-up centers adding a remote ECG option for executive screening. Telehealth providers pairing physician review with patient-recorded ECGs.

Clinics can obtain a synthesized 12-lead ECG from a portable, cable-free device without a patient visit. Recordings are reviewed by a physician, which supports faster cardiologist interpretation. The small form factor lets patients record anywhere, and the data is clinical-grade for arrhythmia assessment.

Cardiology practices are moving arrhythmia and ischemia checks from the clinic to the home, driven by wearable ECG clearances and remote monitoring reimbursement. In Vietnam and Southeast Asia, cardiovascular disease is a leading health burden and access to cardiologists outside major cities is limited, which creates demand for portable ECG with remote reading.

HeartBeam, Inc. is headquartered in Santa Clara, California and listed on NASDAQ (BEAT). FDA cleared the 3D ECG technology in December 2024 and the 12-lead synthesis software in December 2025. First commercial partner is ClearCardio; AI-ECG collaboration with Mount Sinai. Founding year not stated on fetched pages.